Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374254 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
A Phase 1 study of Metastatic Colorectal Cancer, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 14
- Study locations
NCT03374254 is a Phase 1 study of Metastatic Colorectal Cancer that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 116 participants, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (37% lower). The trial reports 14 study locations across 12 states.
The verdict
NCT03374254, a Phase 1 study of Metastatic Colorectal Cancer, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus mFOLFOX7 (oxaliplatin 85 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; fluorouracil \[5-FU\] 2400 mg/m\^2) (Cohort B), pembrolizumab plus mFOLFOX7 and binimetinib (Cohort C), pembrolizumab plus FOLFIRI (irinotecan 180 mg/m\^2; leucovorin \[calcium folinate\]400 mg/m\^2; 5-FU 2400 mg/m\^2 over 46-48 hours) (Cohort D), and pembrolizumab plus FOLFIRI and binimetinib (Cohort E).
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Binimetinib
- DRUG 5-Fluorouracil [5-FU]
Study Locations (14)
Washington
- Seattle Cancer Care Alliance ( Site 0104) - Seattle
- Northwest Medical Specialties, PLLC ( Site 0101) - Tacoma
Quebec
- Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0124) - Montreal
- Jewish General Hospital ( Site 0121) - Montreal
California
- City of Hope National Medical Center ( Site 0102) - Duarte
Colorado
- Anschutz Medical Campus, Anschutz Cancer Pavilion ( Site 0106) - Aurora
Connecticut
- Yale Cancer Center ( Site 0108) - New Haven
Florida
- Moffitt Cancer Center ( Site 0111) - Tampa
Illinois
- University of Chicago ( Site 0105) - Chicago
New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0107) - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2018-02-16 |
| Est. Completion | 2023-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374254
The ClinicalTrials.gov registry entry for NCT03374254 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (37% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03374254 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Washington, Quebec, California.
Frequently Asked Questions
What is clinical trial NCT03374254 about?
NCT03374254 is a clinical study titled "Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)". The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus mFOLFOX7 (oxaliplatin 85 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2...
What is the current status of trial NCT03374254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2018-02-16. Estimated completion is 2023-07-18.
What conditions does trial NCT03374254 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT03374254?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Leucovorin (DRUG), Oxaliplatin (DRUG), Binimetinib (DRUG), 5-Fluorouracil [5-FU] (DRUG).
Who is sponsoring clinical trial NCT03374254?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03374254 being conducted?
This trial has 14 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.